Search
Doravirine
go.drugbank.com/drugs/DB12301ApprovedInvestigationalDoravirine is an HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) intended to be administered in combination with other antiretroviral medicines.
Categories: Non-Nucleoside Reverse Transcriptase Inhibitors, Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase InhibitorPlerixafor
go.drugbank.com/drugs/DB06809ApprovedInvestigational[A7117,L45678] It is used to stimulate the release of stem cells from the bone marrow into the blood in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma to stimulate their immune system. … [A7115] Plerixafor has orphan drug status in the United States and European Union and was approved by the US Food and Drug Administration on December 15, 2008.[A7117,L45678]
Isatuximab
go.drugbank.com/drugs/DB14811ApprovedInvestigationalgranted Orphan Drug designation and approved on March 2nd, 2020, for the treatment of multiple myeloma. … [L12099] It is a cytolytic antibody targeted against CD38, a glycoprotein found on the surface of some immune cells that is highly expressed by malignant plasma cells in multiple myeloma.
Lorlatinib
go.drugbank.com/drugs/DB12130ApprovedInvestigationalLorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer[L39905] which was first approved by the US FDA in November of 2018 … It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to
Naxitamab
go.drugbank.com/drugs/DB15965ApprovedInvestigational[L24929] Naxitamab-gqgk (Danyelza) was granted accelerated approval by the FDA in November 2020 for the treatment of high-risk relapsed/refractory neuroblastoma of the bone or bone marrow.
Loperamide
go.drugbank.com/drugs/DB00836ApprovedInvestigational[A251610] It is a highly lipophilic synthetic phenylpiperidine opioid that works by binding to mu-opioid receptors on intestinal muscles to decrease intestinal motility and electrolyte loss. … [A251610] Loperamide has a chemical structure that is similar to diphenoxylate and haloperidol;[A6249] however, loperamide works on mu (μ)-opioid receptors to mediate its pharmacological actions.
Mixtures: Doc in the Box All Day Supply, Meds on the GoPalbociclib
go.drugbank.com/drugs/DB09073ApprovedInvestigational[L5867] It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male … patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
Teriparatide
go.drugbank.com/drugs/DB06285ApprovedInvestigationalTeriparatide is a recombinant parathyroid hormone (PTH) analog and a potent osteoanabolic agent. It is made up of the first amino(N)-terminal 34 amino acids of the human PTH. First approved in the United States in November 2002 and in Eu...
Categories: Bone Anabolic Agents, Bone Density Conservation AgentsDanicopan
go.drugbank.com/drugs/DB15401ApprovedInvestigational[A263506] It was subsequently approved by the FDA in March 2024.[L50386] … Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired hematologic disease characterized by hemolysis, thrombophilia, and bone marrow dysfunction.
Ketorolac
go.drugbank.com/drugs/DB00465ApprovedInvestigationalKetorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-Narcotic